Eliminate mitochondrial diseases by gene editing in germ-line cells and embryos
Authors:
Open Access
- 17 June 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 6 (7) , 472-475
Abstract
Nuclease-based gene editing technologies have opened up opportunities for correcting human genetic diseases. For the first time, scientists achieved targeted gene editing of mitochondrial DNA in mouse oocytes fused with patient cells. This fascinating progression may encourage the development of novel therapy for human maternally inherent mitochondrial diseases.Keywords
This publication has 24 references indexed in Scilit:
- CRISPR/Cas9-mediated gene editing in human tripronuclear zygotesProtein & Cell, 2015
- Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophyNature Communications, 2015
- Efficient Ablation of Genes in Human Hematopoietic Stem and Effector Cells using CRISPR/Cas9Cell Stem Cell, 2014
- RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infectionProceedings of the National Academy of Sciences, 2014
- Modelling Fanconi anemia pathogenesis and therapeutics using integration-free patient-derived iPSCsNature Communications, 2014
- Generation of Gene-Modified Cynomolgus Monkey via Cas9/RNA-Mediated Gene Targeting in One-Cell EmbryosCell, 2014
- One-step generation of knockout pigs by zygote injection of CRISPR/Cas systemCell Research, 2014
- Progressive degeneration of human neural stem cells caused by pathogenic LRRK2Nature, 2012
- Efficient correction of hemoglobinopathy-causing mutations by homologous recombination in integration-free patient iPSCsCell Research, 2011
- Targeted Gene Correction of Laminopathy-Associated LMNA Mutations in Patient-Specific iPSCsCell Stem Cell, 2011